VolitionRX Ltd Company Profile (NASDAQ:VNRX)

About VolitionRX Ltd

VolitionRX Ltd logoVolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The Company's Nucleosomics biomarker platform is a technology that is used for a range of cancers. The Company is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The Company's NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T. It has developed approximately two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VNRX
  • CUSIP:
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $
  • 200 Day Moving Average: $
  • 52-Week Range: $3.05 - $5.86
  • Trailing P/E Ratio:
  • Foreward P/E Ratio: -9.33
  • P/E Growth:
  • Market Cap: $
  • Outstanding Shares: 23,521,000
Additional Links:

Analyst Ratings

Consensus Ratings for VolitionRX Ltd (NASDAQ:VNRX) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00 (106.19% upside)

Analysts' Ratings History for VolitionRX Ltd (NASDAQ:VNRX)
DateFirmActionRatingPrice TargetDetails
9/8/2016HC WainwrightSet Price TargetBuy$10.00View Rating Details
9/7/2016Rodman & RenshawReiterated RatingBuy$12.00 -> $10.00View Rating Details
(Data available from 10/22/2014 forward)


Earnings History for VolitionRX Ltd (NASDAQ:VNRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/11/2016Q216($0.12)($0.13)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for VolitionRX Ltd (NASDAQ:VNRX)
Current Year EPS Consensus Estimate: $-0.56 EPS
Next Year EPS Consensus Estimate: $-0.52 EPS


Dividend History for VolitionRX Ltd (NASDAQ:VNRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for VolitionRX Ltd (NASDAQ:VNRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/5/2016David Matthew KratochvilCFOBuy10,000$5.00$50,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for VolitionRX Ltd (NASDAQ:VNRX)
finance.yahoo.com logoVNRX: Several Key Milestones for 2016 Including European Launch (NASDAQ:VNRX)
finance.yahoo.com - March 14 at 11:20 AM
finance.yahoo.com logoVolitionRx Announces Full Year 2015 Financial Results and Business Update (NASDAQ:VNRX)
finance.yahoo.com - March 11 at 7:35 AM
biz.yahoo.com logoVOLITIONRX LTD Files SEC form 10-K, Annual Report (NASDAQ:VNRX)
biz.yahoo.com - March 11 at 6:04 AM
finance.yahoo.com logoVolitionRx Schedules Full-Year 2015 Earnings Conference Call and Business Update for Friday, March 11, 2016 at 8:30am ET (NASDAQ:VNRX)
finance.yahoo.com - March 9 at 8:30 AM
finance.yahoo.com logoPreliminary Data Demonstrates 86% Accuracy in Detecting Idiopathic Pulmonary Fibrosis, a Fatal Lung Disease (NASDAQ:VNRX)
finance.yahoo.com - March 9 at 7:00 AM
finance.yahoo.com logoVolitionRx Demonstrates 75% Accuracy in Detecting Highest-Risk Pre-Cancerous Colorectal Adenomas with NuQ® Blood Test (NASDAQ:VNRX)
finance.yahoo.com - February 17 at 7:00 AM
News IconVolitionRx initiates study to assess NuQ blood tests for detection of prostate cancer (NASDAQ:VNRX)
www.news-medical.net - February 5 at 1:37 PM
prnewswire.com logoVolitionRx and Cancer Survivor Sean Swarner Celebrate World Cancer Day with Message of Hope for Cancer Survival Through Early Detection (NASDAQ:VNRX)
www.prnewswire.com - February 4 at 1:30 PM
finance.yahoo.com logo/C O R R E C T I O N -- VolitionRx Ltd/ (NASDAQ:VNRX)
finance.yahoo.com - February 4 at 8:00 AM
finance.yahoo.com logoVNRX: More Positive Trial Data in Colon/Lung Cancers (NASDAQ:VNRX)
finance.yahoo.com - February 2 at 3:45 PM
finance.yahoo.com logo7:03 am VolitionRx collaborates with Surrey Cancer Research Institute to initiate prostate cancer study (NASDAQ:VNRX)
finance.yahoo.com - February 2 at 7:03 AM
finance.yahoo.com logoVolitionRx Initiates Prostate Cancer Study in Collaboration with the Surrey Cancer Research Institute, University of Surrey, UK (NASDAQ:VNRX)
finance.yahoo.com - February 2 at 7:00 AM
finance.yahoo.com logoCoverage initiated on VolitionRx by Rodman & Renshaw (NASDAQ:VNRX)
finance.yahoo.com - February 1 at 7:08 AM
finance.yahoo.com logoVolitionRx Receives International ISO Certification for Quality Management System of its NuQ(R) Blood Tests (NASDAQ:VNRX)
finance.yahoo.com - January 28 at 7:00 AM
finance.yahoo.com logoVolitionRx Releases Annual Shareholder Update Letter (NASDAQ:VNRX)
finance.yahoo.com - January 13 at 7:00 AM
finance.yahoo.com logoEXCLUSIVE: VolitionRX CEO Talks Trial Updates, Time Until Market (NASDAQ:VNRX)
finance.yahoo.com - January 6 at 9:00 AM
biz.yahoo.com logoVOLITIONRX LTD Files SEC form 8-K, Financial Statements and Exhibits (NASDAQ:VNRX)
biz.yahoo.com - January 5 at 5:04 PM
finance.yahoo.com logoVolitionRx Announces Dr. Jason Terrell's Transition to Full-Time Status as Chief Medical Officer and Head of U.S. Operations (NASDAQ:VNRX)
finance.yahoo.com - January 5 at 7:00 AM
finance.yahoo.com logoVolitionRx Granted Its Third U.S. Patent (NASDAQ:VNRX)
finance.yahoo.com - January 4 at 7:00 AM
finance.yahoo.com logoVOLITIONRX LTD Financials (NASDAQ:VNRX)
finance.yahoo.com - December 8 at 1:17 PM
finance.yahoo.com logoVolitionRx Demonstrates More Than 90% Accuracy for Colorectal Cancer NuQ(R) Blood Test in Completed Prospective Study (NASDAQ:VNRX)
finance.yahoo.com - December 8 at 7:00 AM
finance.yahoo.com logoVolitionRx to Present at LD Micro Conference on December 3 in Los Angeles (NASDAQ:VNRX)
finance.yahoo.com - November 30 at 7:00 AM
biz.yahoo.com logoVOLITIONRX LTD Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:VNRX)
biz.yahoo.com - November 24 at 4:05 PM
finance.yahoo.com logoVolitionRx Demonstrates NuQ® Blood Test Detects Lung Cancers with more than 90% Accuracy (NASDAQ:VNRX)
finance.yahoo.com - November 19 at 7:00 AM
finance.yahoo.com logoVolitionRx Granted Its Second U.S. Patent (NASDAQ:VNRX)
finance.yahoo.com - November 17 at 9:00 AM
finance.yahoo.com logoVolitionRx to Present at Two Conferences in November (NASDAQ:VNRX)
finance.yahoo.com - November 12 at 7:00 AM
biz.yahoo.com logoVOLITIONRX LTD Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:VNRX)
biz.yahoo.com - November 10 at 5:20 PM
finance.yahoo.com logoVolitionRx Announces Third Quarter 2015 Financial Results and Business Update (NASDAQ:VNRX)
finance.yahoo.com - November 4 at 6:30 AM
biz.yahoo.com logoVOLITIONRX LTD Files SEC form 10-Q, Quarterly Report (NASDAQ:VNRX)
biz.yahoo.com - November 4 at 6:10 AM


VolitionRX Ltd (NASDAQ:VNRX) Chart for Saturday, October, 22, 2016

Last Updated on 10/22/2016 by MarketBeat.com Staff